ATE522540T1 - Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheiten - Google Patents

Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheiten

Info

Publication number
ATE522540T1
ATE522540T1 AT07718885T AT07718885T ATE522540T1 AT E522540 T1 ATE522540 T1 AT E522540T1 AT 07718885 T AT07718885 T AT 07718885T AT 07718885 T AT07718885 T AT 07718885T AT E522540 T1 ATE522540 T1 AT E522540T1
Authority
AT
Austria
Prior art keywords
short interfering
interfering ribonucleic
treatment
ribonucleic acids
gene rna
Prior art date
Application number
AT07718885T
Other languages
English (en)
Inventor
Bor-Luen Chiang
Chung-Sheng Huang
Original Assignee
Wholesome Biopharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006902491A external-priority patent/AU2006902491A0/en
Application filed by Wholesome Biopharm Pty Ltd filed Critical Wholesome Biopharm Pty Ltd
Application granted granted Critical
Publication of ATE522540T1 publication Critical patent/ATE522540T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07718885T 2006-05-11 2007-05-11 Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheiten ATE522540T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006902491A AU2006902491A0 (en) 2006-05-11 Short interference ribonucleic acids for treating allergic diseases
PCT/AU2007/000638 WO2007131274A1 (en) 2006-05-11 2007-05-11 Short interference ribonucleic acids for treating allegic diseases

Publications (1)

Publication Number Publication Date
ATE522540T1 true ATE522540T1 (de) 2011-09-15

Family

ID=38693443

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07718885T ATE522540T1 (de) 2006-05-11 2007-05-11 Kurze interferierende ribonukleinsäuren zur behandlung allergischer krankheiten

Country Status (8)

Country Link
US (1) US8188262B2 (de)
EP (1) EP2018395B1 (de)
JP (1) JP2009536518A (de)
CN (1) CN101437835B (de)
AT (1) ATE522540T1 (de)
ES (1) ES2372982T3 (de)
TW (1) TWI322690B (de)
WO (1) WO2007131274A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120029054A1 (en) * 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
JP2013079210A (ja) * 2011-10-04 2013-05-02 Nagoya City Univ 治療剤、遺伝子治療剤及び好酸球の浸潤抑制方法
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
WO2015051318A1 (en) 2013-10-04 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
US20150376612A1 (en) * 2014-06-10 2015-12-31 The General Hospital Corporation CCCTC-Binding Factor (CTCF) RNA Interactome
PL3093022T3 (pl) * 2015-05-15 2020-02-28 Sterna Biologicals Gmbh & Co. Kg Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2
RU2615463C1 (ru) * 2016-01-28 2017-04-04 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Способ лечения аллергической бронхиальной астмы, основанный на подавлении экспрессии генов цитокинов IL-4 и IL-13 с использованием молекул миРНК

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034887A2 (en) * 1995-05-05 1996-11-07 Imperial College Of Science, Technology & Medicine Antisense peptides
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
AU2002256359A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050261219A1 (en) * 2001-05-18 2005-11-24 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
EP2305813A3 (de) 2002-11-14 2012-03-28 Dharmacon, Inc. Funktionale und hyperfunktionale siRNA
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same

Also Published As

Publication number Publication date
TW200806302A (en) 2008-02-01
HK1130065A1 (en) 2009-12-18
US20090264503A1 (en) 2009-10-22
US8188262B2 (en) 2012-05-29
CN101437835A (zh) 2009-05-20
CN101437835B (zh) 2012-10-10
JP2009536518A (ja) 2009-10-15
WO2007131274A1 (en) 2007-11-22
AU2007250524B2 (en) 2012-11-01
AU2007250524A1 (en) 2007-11-22
EP2018395A4 (de) 2009-12-09
EP2018395B1 (de) 2011-08-31
TWI322690B (en) 2010-04-01
ES2372982T3 (es) 2012-01-30
EP2018395A1 (de) 2009-01-28

Similar Documents

Publication Publication Date Title
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
EA200870528A1 (ru) Композиции и способы ингибирования экспрессии гена pcsk9
WO2013074974A3 (en) Modified rnai agents
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
WO2009050506A3 (en) Combination 059
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
TW201712023A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
EA200870401A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5
WO2004065601A3 (en) Lipophilic derivatives of double-stranded ribonucleic acid
TW200806302A (en) Short interference ribonucleic acids for treating allergic dieases
WO2019217397A3 (en) Compositions and methods for improving strand biased
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
WO2012046085A3 (en) Methods of inducing insulin production
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2008036638A3 (en) Rnai modulation of scap and therapeutic uses thereof
WO2007137156A3 (en) Rnai modulation of aha and therapeutic uses thereof
MY149171A (en) Treatment and prevention of influenza
WO2010003420A3 (en) Treatment of psoriasis and related diseases by mirna modulation
WO2006093547A3 (en) Novel lipoxygenase inhibitors
WO2011087835A3 (en) Novel compositions and methods for treating inflammatory bowel disease and airway inflammation
WO2011045573A3 (en) Staphylococcal antigens
WO2008051523A3 (en) Carbazole derivatives useful as medicaments in cancer therapy
WO2009138146A3 (de) Neue therapeutika für die hepatitis-therapie
WO2009012785A3 (en) Complexes of an emulgator and a fatty acid
WO2005001031A3 (en) Modulation of the rna interference pathway

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties